Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...